1. Home
  2. PBMWW vs HCI Comparison

PBMWW vs HCI Comparison

Compare PBMWW & HCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBMWW
  • HCI
  • Stock Information
  • Founded
  • PBMWW N/A
  • HCI 2006
  • Country
  • PBMWW Canada
  • HCI United States
  • Employees
  • PBMWW 10
  • HCI N/A
  • Industry
  • PBMWW
  • HCI Property-Casualty Insurers
  • Sector
  • PBMWW
  • HCI Finance
  • Exchange
  • PBMWW Nasdaq
  • HCI Nasdaq
  • Market Cap
  • PBMWW N/A
  • HCI N/A
  • IPO Year
  • PBMWW N/A
  • HCI N/A
  • Fundamental
  • Price
  • PBMWW $0.02
  • HCI $121.77
  • Analyst Decision
  • PBMWW
  • HCI Buy
  • Analyst Count
  • PBMWW 0
  • HCI 5
  • Target Price
  • PBMWW N/A
  • HCI $140.00
  • AVG Volume (30 Days)
  • PBMWW N/A
  • HCI 137.0K
  • Earning Date
  • PBMWW N/A
  • HCI 03-06-2025
  • Dividend Yield
  • PBMWW N/A
  • HCI 1.31%
  • EPS Growth
  • PBMWW N/A
  • HCI 163.93
  • EPS
  • PBMWW N/A
  • HCI 11.94
  • Revenue
  • PBMWW N/A
  • HCI $750,846,000.00
  • Revenue This Year
  • PBMWW N/A
  • HCI N/A
  • Revenue Next Year
  • PBMWW N/A
  • HCI $14.52
  • P/E Ratio
  • PBMWW N/A
  • HCI $10.19
  • Revenue Growth
  • PBMWW N/A
  • HCI 48.73
  • 52 Week Low
  • PBMWW N/A
  • HCI $83.65
  • 52 Week High
  • PBMWW N/A
  • HCI $126.50
  • Technical
  • Relative Strength Index (RSI)
  • PBMWW N/A
  • HCI 60.96
  • Support Level
  • PBMWW N/A
  • HCI $109.43
  • Resistance Level
  • PBMWW N/A
  • HCI $115.99
  • Average True Range (ATR)
  • PBMWW 0.00
  • HCI 4.34
  • MACD
  • PBMWW 0.00
  • HCI 0.87
  • Stochastic Oscillator
  • PBMWW 0.00
  • HCI 93.17

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: